Published in Genes Chromosomes Cancer on April 01, 2009
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res (2010) 1.71
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest (2010) 1.48
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res (2012) 1.40
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res (2013) 1.16
The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl (2013) 1.11
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res (2011) 0.99
Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays. Nucleic Acids Res (2010) 0.98
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene (2015) 0.95
SPOP mutation leads to genomic instability in prostate cancer. Elife (2015) 0.93
Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet (2012) 0.90
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med (2013) 0.90
The genomic landscape of prostate cancer. Int J Mol Sci (2013) 0.88
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol (2013) 0.86
A magnetic bead-based protein kinase assay with dual detection techniques. Anal Biochem (2010) 0.84
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget (2015) 0.78
Myosins as fundamental components during tumorigenesis: diverse and indispensable. Oncotarget (2016) 0.78
Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget (2016) 0.75
Myosin VI contributes to malignant proliferation of human glioma cells. Korean J Physiol Pharmacol (2016) 0.75
Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. PLoS One (2015) 0.75
A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. Nat Genet (2017) 0.75
Advances in genetics: widening our understanding of prostate cancer. F1000Res (2016) 0.75
Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. Cancer Cell (2013) 0.75
Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol (2001) 15.02
Cancer statistics, 2001. CA Cancer J Clin (2001) 11.73
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
High-resolution mapping of DNA copy alterations in human chromosome 22 using high-density tiling oligonucleotide arrays. Proc Natl Acad Sci U S A (2006) 4.84
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature (1984) 4.35
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Systematic prediction and validation of breakpoints associated with copy-number variants in the human genome. Proc Natl Acad Sci U S A (2007) 3.35
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J (1993) 2.91
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer (2007) 2.65
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol (2007) 2.17
MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell (1996) 2.08
Assessing the need for sequence-based normalization in tiling microarray experiments. Bioinformatics (2007) 2.08
MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene (2006) 2.07
Mcm10 and the MCM2-7 complex interact to initiate DNA synthesis and to release replication factors from origins. Genes Dev (2000) 2.04
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Prognostic factors in lymph node-positive prostate cancer. Urology (2006) 1.66
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer (2006) 1.58
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res (2008) 1.51
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate (2008) 1.42
Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene (2006) 1.35
Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol (1996) 1.32
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate (2001) 1.23
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Chromosomal aberrations in prostate cancer. Front Biosci (2007) 1.07
Maf transcriptionally activates the mouse p53 promoter and causes a p53-dependent cell death. J Biol Chem (2000) 1.05
c-Maf interacts with c-Myb to down-regulate Bcl-2 expression and increase apoptosis in peripheral CD4 cells. Eur J Immunol (2007) 0.96
Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate (2003) 0.94
Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer (1994) 0.93
Migrating with myosin VI. Am J Pathol (2006) 0.90
Sorting nexin-14, a gene expressed in motoneurons trapped by an in vitro preselection method. Dev Dyn (2001) 0.89
Mutational analysis of ETV6 in prostate carcinoma. Prostate (2002) 0.89
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77
Global variation in copy number in the human genome. Nature (2006) 57.50
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
The transcriptional landscape of the yeast genome defined by RNA sequencing. Science (2008) 48.99
Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods (2007) 45.04
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 36.10
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Paired-end mapping reveals extensive structural variation in the human genome. Science (2007) 30.46
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Origins and functional impact of copy number variation in the human genome. Nature (2009) 23.63
Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 23.38
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Global identification of human transcribed sequences with genome tiling arrays. Science (2004) 17.85
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet (2008) 15.89
Common deletion polymorphisms in the human genome. Nat Genet (2006) 15.66
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet (2010) 13.70
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
A global reference for human genetic variation. Nature (2015) 12.85
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
A systematic survey of loss-of-function variants in human protein-coding genes. Science (2012) 12.25
A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science (2003) 12.07
Unlocking the secrets of the genome. Nature (2009) 11.80
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Annotation of functional variation in personal genomes using RegulomeDB. Genome Res (2012) 11.47
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat Biotechnol (2009) 11.28
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
High-quality binary protein interaction map of the yeast interactome network. Science (2008) 10.65
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
EMBL Nucleotide Sequence Database in 2006. Nucleic Acids Res (2006) 9.72
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Variation in transcription factor binding among humans. Science (2010) 9.33
Genomic analysis of regulatory network dynamics reveals large topological changes. Nature (2004) 9.32
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res (2012) 9.13
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86